Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Magnesium citrate powder in laxatives

This article was originally published in The Tan Sheet

Executive Summary

Magnesium citrate powder in laxatives: U.S. Pharmacopeia revision committee approves draft monograph for magnesium citrate powder oral solution. The monograph is published in the May-June Pharmacopeial Forum, Purdue Frederick tells FDA in a May 6 resubmitted citizen petition. The petition seeks inclusion of the ingredient in the laxative monograph. The company submitted its original petition in October 1994. Two months later, FDA denied the request, expressing concerns about solubility and the safety of the dosage form. The agency also suggested that the company develop a USP monograph and resubmit the petition ("The Tan Sheet" Jan. 9, 1995, p. 10). The petition requests clarification that the saline active ingredient magnesium citrate may be supplied in any dosage form, including a solid mixture to be reconstituted prior to oral administration...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel